Study Details
Full Title
[RMC-9805-305] A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
Principal Investigator
Niharika
Mettu
Protocol Number
PRO00120109
NCT ID
NCT07621718
Phase
III
Enrollment Status
Open to Enrollment